Genenta Science S.P.A. ADR (GNTA)

$6.20 +2.97 (91.95%)
Market Cap 61.84M
Revenue (ttm) 0.00
Net Income (ttm) -9.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 21,875,000
Avg Vol 450,320
Day's Range N/A - N/A
Shares Out 19.15M
Stochastic %K 45%
Beta 0.58
Analysts Strong Sell
Price Target $23.00

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...

Industry: Biotechnology
Sector: Healthcare
Phone: 39 02 26434681
Address:
Via Olgettina No. 58, Milan, Italy
UgoGreg
UgoGreg Oct. 25 at 11:30 AM
$GNTA https://youtu.be/GOBtvYqJjAM
0 · Reply
StockFlips
StockFlips Oct. 25 at 9:40 AM
Guten Morgan ☕️ I’m bringing out Study Saturday today. If you want to learn how to read charts at a level that is fairly easy to understand then grab a follow. 🫵 If you want to show up to the game like a darkhorse on fire; about whom little is known but who unexpectedly wins or succeeds… then grab a seat please. Later today I’ll be sharing some bullish setups for the near future, all in chart form. Technicals only. If you want to be early to some potentially massive gainers like $NERV $SCNX $GNTA $AREB $BYND then I recommend paying attention later. Be EARLY, don’t be GREEDY 🫵
1 · Reply
MadMaverick
MadMaverick Oct. 25 at 4:36 AM
⚡WATCHLIST RECAP⚡ $WGRX $GNTA $VIVK $QLGN
0 · Reply
Valentino1863
Valentino1863 Oct. 24 at 11:49 PM
$GNTA
0 · Reply
VMAESA
VMAESA Oct. 24 at 11:15 PM
$GNTA Know when to short & when to wait👇 We absolutely destroyed this short today🎯 Link in bio to learn
0 · Reply
KillerTrader
KillerTrader Oct. 24 at 10:49 PM
$GNTA 349 k traded in AF, algos push Down, he's the only one trading, no buyers, it looks like the classic pump and dump...or maybe they want shares, to cover themselves, we'll see Monday
1 · Reply
basereport
basereport Oct. 24 at 10:45 PM
🚀 Strongest stocks of the day Start tracking these today using our free stock screener: https://base.report/screener?filter_key=IJQVaoxW $WGRX $INBX $GNTA $NEUP
0 · Reply
Valentino1863
Valentino1863 Oct. 24 at 10:40 PM
$GNTA monster runner today congrats bulls
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 10:29 PM
Top Gainers $WGRX $INBX $GNTA $MAMK $NEUP
0 · Reply
Jack20202
Jack20202 Oct. 24 at 10:26 PM
$GNTA Why is this down 20.65% after hours, if anybody knows ?????
1 · Reply
Latest News on GNTA
Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Oct 24, 2025, 4:00 AM EDT - 1 day ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Jul 1, 2025, 5:00 AM EDT - 4 months ago

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 7:00 AM EDT - 6 months ago

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

May 7, 2025, 7:00 AM EDT - 6 months ago

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Apr 15, 2025, 5:00 AM EDT - 6 months ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Mar 19, 2025, 9:28 AM EDT - 7 months ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 28, 2025, 8:01 AM EST - 9 months ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 9, 2025, 6:00 AM EST - 10 months ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 8, 2025, 3:17 PM EST - 10 months ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Genenta Welcomes New Directors John L. Cantello, Lauren H.

May 6, 2024, 6:25 AM EDT - 1 year ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Feb 8, 2024, 5:00 AM EST - 1 year ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Genenta to Present at Upcoming Scientific and Investor Conferences

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jul 28, 2023, 3:00 AM EDT - 2 years ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Jun 29, 2023, 7:00 AM EDT - 2 years ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Apr 3, 2023, 7:00 AM EDT - 2 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Mar 2, 2023, 6:45 AM EST - 2 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Feb 7, 2023, 7:00 AM EST - 2 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Nov 7, 2022, 8:05 AM EST - 3 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Genenta Provides First Half 2022 Business Update and Financial Results

Oct 24, 2022, 7:30 AM EDT - 3 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Genenta to Present at Upcoming Investor Conferences

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Genenta to Present at Upcoming Investor Conferences

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Jul 25, 2022, 6:00 AM EDT - 3 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 13, 2022, 7:30 AM EDT - 3 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 9, 2022, 7:30 AM EDT - 3 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 4:30 PM EDT - 3 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 4, 2022, 7:30 AM EDT - 3 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

May 2, 2022, 4:30 PM EDT - 3 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 27, 2022, 7:30 AM EDT - 3 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Apr 20, 2022, 7:30 AM EDT - 3 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Mar 9, 2022, 7:46 AM EST - 3 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Genenta to Participate at Upcoming Investor Conferences

Feb 24, 2022, 7:30 AM EST - 3 years ago

Genenta to Participate at Upcoming Investor Conferences

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 17, 2021, 4:15 PM EST - 4 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Genenta Announces Pricing of Upsized Initial Public Offering

Dec 14, 2021, 10:36 PM EST - 4 years ago

Genenta Announces Pricing of Upsized Initial Public Offering

UgoGreg
UgoGreg Oct. 25 at 11:30 AM
$GNTA https://youtu.be/GOBtvYqJjAM
0 · Reply
StockFlips
StockFlips Oct. 25 at 9:40 AM
Guten Morgan ☕️ I’m bringing out Study Saturday today. If you want to learn how to read charts at a level that is fairly easy to understand then grab a follow. 🫵 If you want to show up to the game like a darkhorse on fire; about whom little is known but who unexpectedly wins or succeeds… then grab a seat please. Later today I’ll be sharing some bullish setups for the near future, all in chart form. Technicals only. If you want to be early to some potentially massive gainers like $NERV $SCNX $GNTA $AREB $BYND then I recommend paying attention later. Be EARLY, don’t be GREEDY 🫵
1 · Reply
MadMaverick
MadMaverick Oct. 25 at 4:36 AM
⚡WATCHLIST RECAP⚡ $WGRX $GNTA $VIVK $QLGN
0 · Reply
Valentino1863
Valentino1863 Oct. 24 at 11:49 PM
$GNTA
0 · Reply
VMAESA
VMAESA Oct. 24 at 11:15 PM
$GNTA Know when to short & when to wait👇 We absolutely destroyed this short today🎯 Link in bio to learn
0 · Reply
KillerTrader
KillerTrader Oct. 24 at 10:49 PM
$GNTA 349 k traded in AF, algos push Down, he's the only one trading, no buyers, it looks like the classic pump and dump...or maybe they want shares, to cover themselves, we'll see Monday
1 · Reply
basereport
basereport Oct. 24 at 10:45 PM
🚀 Strongest stocks of the day Start tracking these today using our free stock screener: https://base.report/screener?filter_key=IJQVaoxW $WGRX $INBX $GNTA $NEUP
0 · Reply
Valentino1863
Valentino1863 Oct. 24 at 10:40 PM
$GNTA monster runner today congrats bulls
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 10:29 PM
Top Gainers $WGRX $INBX $GNTA $MAMK $NEUP
0 · Reply
Jack20202
Jack20202 Oct. 24 at 10:26 PM
$GNTA Why is this down 20.65% after hours, if anybody knows ?????
1 · Reply
Rvazstocksfl
Rvazstocksfl Oct. 24 at 10:19 PM
$GNTA lol back to 1
0 · Reply
Dngang82
Dngang82 Oct. 24 at 9:46 PM
$PMI this is just warming up. The real party will be Monday. $INBX $GNTA
0 · Reply
mcewing
mcewing Oct. 24 at 9:33 PM
$GNTA $6 ave not looking so
1 · Reply
BrunetteSara
BrunetteSara Oct. 24 at 8:47 PM
$CMCT Next nano floater runner!! Worth to watch ;) $GNTA & $INBX Did great today congrats bulls...
0 · Reply
stockbot1234
stockbot1234 Oct. 24 at 8:39 PM
$GNTA on vacation, but some shorts will enter the Short Hall of Fame for this play! $44 to $5! Wow!😮
1 · Reply
UnicornProfits
UnicornProfits Oct. 24 at 8:34 PM
What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $WGRX $INBX $GNTA $MAMK ----
0 · Reply
BigPablo2025
BigPablo2025 Oct. 24 at 8:32 PM
$GNTA frame that picture below, what a disaster, only people made money after it hit 40 was the shorts
1 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 24 at 8:21 PM
$GNTA took small loss Good luck all
0 · Reply
Donniechen12345
Donniechen12345 Oct. 24 at 8:17 PM
$GNTA this is why you need to sell at 12:59 lmao out at $6.10 lol
0 · Reply
Celz
Celz Oct. 24 at 8:12 PM
$GNTA scam stock
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 8:06 PM
Top Gainers $WGRX $INBX $MAMK $GNTA $NEUP
0 · Reply
BenGang
BenGang Oct. 24 at 8:01 PM
$GNTA Check out $GOSS
0 · Reply